Federation Des Caisses Desjardins Du Quebec Horizon Therapeutics Public LTD CO Transaction History

Federation Des Caisses Desjardins Du Quebec

$18.9 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 14, 2024	SELL	$0.0 - $116.3 $0 - $92,109	-792 Closed	0 $0
Q2 2023 Aug 14, 2024	SELL	$96.34 - $112.38 $36,801 - $42,929	-382 Reduced 32.54%	792 $81.5 Million
Q1 2023 Aug 14, 2024	BUY	$107.32 - $113.5 $58,167 - $61,517	542 Added 85.76%	1,174 $128 Million
Q4 2022 Aug 14, 2024	SELL	$62.39 - $113.8 $107,809 - $196,646	-1,728 Reduced 73.22%	632 $71.9 Million
Q3 2022 Aug 14, 2024	SELL	$58.92 - $84.67 $14,081 - $20,236	-239 Reduced 9.2%	2,360 $146 Million
Q2 2022 Aug 14, 2024	BUY	$79.4 - $116.36 $91,151 - $133,581	1,148 Added 79.12%	2,599 $207 Million
Q1 2022 Aug 14, 2024	BUY	$86.42 - $109.81 $125,395 - $159,334	1,451 New	1,451 $153 Million
Q4 2021 Aug 30, 2024	BUY	$98.56 - $119.91 $4,928 - $5,995	50 Added 4.21%	1,239 $134 Million
Q3 2021 Aug 30, 2024	SELL	$91.91 - $110.37 $105,328 - $126,484	-1,146 Reduced 49.08%	1,189 $130 Million
Q2 2021 Aug 30, 2024	BUY	$86.24 - $95.92 $201,370 - $223,973	2,335 New	2,335 $218 Million
Q1 2021 Aug 30, 2024	BUY	$71.83 - $95.48 $74,703 - $99,299	1,040 Added 47.06%	3,250 $299 Million
Q4 2020 Aug 30, 2024	BUY	$67.0 - $84.39 $148,070 - $186,501	2,210 New	2,210 $162 Million
Q4 2019 Aug 30, 2024	SELL	$25.43 - $36.67 $222,868 - $321,375	-8,764 Closed	0 $0
Q3 2019 Aug 30, 2024	BUY	$23.0 - $27.97 $102,005 - $124,046	4,435 Added 102.45%	8,764 $239 Million
Q2 2019 Aug 30, 2024	BUY	$22.81 - $28.48 $98,744 - $123,289	4,329 New	4,329 $104 Million

Others Institutions Holding HZNP

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

20K

View Full List

About Horizon Therapeutics Public Ltd Co

Ticker HZNP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 230,384,000
Description
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines ...

More about HZNP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Account